Glow-in-OR Drug Exposes Hidden Cancer Tumors

surgeons performing an operation — Photo: Shakirov Albert / Shutterstock

Surgeons are now making hidden lung cancers literally light up in the operating room, and it is quietly changing how they cut, what they remove, and what they leave behind.

Story Snapshot

A fluorescent drug called pafolacianine makes certain lung cancer nodules glow during surgery.
Surgeons found tumors they could not see or feel in about 1 in 5 patients using this technique.
The glow led surgeons to change their surgical plan in nearly 3 out of 10 cases.
Real-world use shows no serious drug-related side effects so far, but questions remain about long-term impact.

Lighting up cancer in the operating room

Mayo Clinic surgeons now walk into lung cancer operations with a new kind of help: a drug that makes many tumors glow under a special camera. The drug, pafolacianine, is given through a vein before surgery. It travels through the body and sticks to cancer cells that carry a specific folate receptor. Under near-infrared light, those cells shine like a tracer on a radar screen, while normal tissue stays dark. This gives surgeons a live map instead of guesswork.

In a major randomized trial, this glowing map mattered. Surgeons using pafolacianine with their usual tools found lung cancer lesions they could not see with white light or feel with their fingers in 19 percent of patients. They also discovered cancerous spots that never showed up on pre-surgery scans in about 8 percent of patients. In plain terms, standard methods missed some tumors, and the glow exposed them in time to cut them out.

Changing how much lung gets removed

Those extra glowing spots did more than surprise surgeons; they changed the operation itself. With pafolacianine imaging, surgeons changed the planned scope of surgery in 29 percent of cases. Sometimes they took a larger piece of lung because they found more disease than expected. In other cases, they could safely remove a smaller segment instead of a whole lobe, because the fluorescent view proved the margins were clear and no other nodules were hiding nearby. That means more lung saved for breathing later.

Follow-up analyses show how these decisions play out in real practice. Clinically significant events tied to the imaging included finding close or positive margins, spotting lesions that did not show up under white light, and revealing hidden malignant nodules elsewhere in the lung. Many of those extra cancers sat outside the original surgical field, which means older methods would likely have left them behind. For early-stage lung cancer, that kind of miss can be the difference between cure and recurrence.

From trial data to real-world use and safety

Doctors have moved quickly from trials to daily use. Real-world reports from lung cancer centers describe a high rate of nodule localization when they add pafolacianine imaging to standard minimally invasive surgery. Surgeons say the glow helps them confidently perform smaller, parenchymal-sparing operations instead of defaulting to larger resections just to “be safe.” For older patients, or anyone with weak lungs, that is not a small detail; it can mean more independence and less time on oxygen.

Safety is the other conservative question: what is the cost of this new tool to the patient’s body? So far, the answer looks reassuring. In the phase 3 ELUCIDATE trial, no serious side effects were tied to pafolacianine. Broader clinical experience now covers more than 700 patients across trials and routine practice, again with no serious treatment-related adverse events reported. That does not mean risk is zero, but it suggests this is not a “fix one problem, create another” situation many Americans rightly fear in modern medicine.

Limits, false alarms, and the bigger picture of surgical tech

Pafolacianine is not magic, and the glow is not a lie detector for cancer. Some fluorescent nodules turn out to be benign on final pathology. Early work reports that only a fraction of occult fluorescent lesions prove malignant, and tumor type matters. Adenocarcinomas are more likely to light up than some other lung cancers, because they often express the folate receptor that this drug targets. That means a dark nodule is not always safe, and a bright one is not always deadly.

This pattern matches a familiar cycle in surgical technology. New imaging tools arrive with headlines about breakthroughs. Over time, doctors learn where they shine and where they fall short. Pafolacianine fits that arc. It clearly improves the surgeon’s eyes for many patients, but proving that it improves long-term survival will take years of follow-up. The key is balance: welcome tools that help doctors cut out more cancer while sparing healthy lung, but stay honest about limits and avoid hype that treats every new device as a miracle. For now, lighting up lung nodules looks like a serious, evidence-based step forward—not science fiction, just smarter surgery.